LIVN — LivaNova PLC

Summary of LivaNova PLC Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $361 million, a 9.5% increase year-over-year on a constant currency and organic basis.
• Full Year Revenue: $1.4 billion, reflecting double-digit growth.
• Adjusted Gross Margin: 68%, consistent with 2024.
• Adjusted Operating Income: $64 million, with an operating margin of 18%, up from 17% in 2024.
• Adjusted Diluted EPS: $0.86, compared to $0.81 in Q4 2024.
• Cash Position: $636 million, up from $429 million at the end of 2024.
• Total Debt: Reduced to $377 million from $628 million in 2024.
• Adjusted Free Cash Flow: $53 million in Q4, $183 million for the full year, up from $163 million in 2024.

2. Strategic Updates and Business Highlights

• Double-Digit Growth: Achieved for the fifth consecutive year in EPS and third consecutive year in organic revenue.
• Cardiopulmonary Segment: Revenue of $207 million in Q4, up 10% year-over-year; full-year revenue grew 13%. Growth driven by strong demand for heart-lung machines and consumables.
• Epilepsy Segment: Revenue increased by 9% in Q4, with a full-year growth of 6%. Strong performance attributed to improved reimbursement rates and clinical evidence from the CORE VNS study.
• Innovation Focus: Continued investment in digital health platforms and new product development, particularly for obstructive sleep apnea (OSA) and difficult-to-treat depression.
• Leadership Strengthening: Appointment of Lucille Blaise as Global Head of Commercialization for OSA.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected between 6% and 7%, consistent with the framework presented at the Investor Day.
• Cardiopulmonary Growth: Projected at 7% to 8%, with continued market share gains and pricing strategies.
• Epilepsy Growth: Forecasted at 5.5% to 6.5%, supported by improved reimbursement and clinical evidence.
• Adjusted Diluted EPS for 2026: Expected in the range of $4.15 to $4.25, representing approximately 8% growth at midpoint.

4. Bad News, Challenges, or Points of Concern

• Supply Constraints: Ongoing third-party supply constraints affecting oxygenator output may limit growth potential.
• Moderation in Pricing: Assumed moderation in pricing for Essence heart-lung machines compared to 2025.
• Reimbursement Risks: Uncertainty regarding reimbursement for new therapies in OSA and difficult-to-treat depression could impact future growth.
• Market Penetration: Despite positive reimbursement changes, procedure penetration for epilepsy remains low, indicating a long road ahead for growth.

5. Notable Q&A Insights

• Oxygenator vs. HLM Growth: Expected double-digit growth from Essence upgrades, with market share gains in consumables.
• Epilepsy Business Dynamics: Increased Medicare reimbursement and CORE VNS study results are expected to drive growth, although new patient volume growth has less impact on overall revenue due to the high proportion of replacement implants.
• Medicaid Reimbursement: Anticipated to follow Medicare trends, but adjustments will take time at the state level.
• Commercial Focus: Plans to reopen previously closed accounts and prioritize value-based discussions over volume in pricing strategies.

This summary encapsulates LivaNova's performance and strategic direction while highlighting both opportunities and challenges as the company moves into 2026.